Last reviewed · How we verify
ketamine 1.5
ketamine 1.5 is a NMDA receptor antagonist Small molecule drug developed by Ajou University School of Medicine. It is currently FDA-approved for General anesthesia, Analgesia and pain management, Treatment-resistant depression (sub-anesthetic doses).
Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks glutamate signaling in the central nervous system.
Ketamine is being studied as a treatment for various conditions, including fractures, dislocations, bone fractures, dislocations, and inguinal hernia, through intranasal administration of Ketodex formulations. It is also being used in combination with dexmedetomidine for procedural sedation in children.
At a glance
| Generic name | ketamine 1.5 |
|---|---|
| Sponsor | Ajou University School of Medicine |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia, Pain Management, Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Ketamine binds to the phencyclidine binding site within the NMDA receptor ion channel pore, blocking the flow of ions and preventing excitatory neurotransmission. This mechanism produces rapid-onset anesthetic, analgesic, and dissociative effects. At sub-anesthetic doses, ketamine has shown rapid-acting antidepressant properties, likely through effects on glutamatergic neurotransmission and downstream neuroplasticity pathways.
Approved indications
- General anesthesia
- Analgesia and pain management
- Treatment-resistant depression (sub-anesthetic doses)
Common side effects
- Dissociation
- Dizziness
- Nausea
- Increased blood pressure
- Emergence reactions
Key clinical trials
- Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine (PHASE3)
- Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy (PHASE2, PHASE3)
- Magnesium Sulfate Versus Other Anesthesia Drugs to Reduce Agitation After Adenotonsillectomy in Pediatric Patients (NA)
- Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery (PHASE3)
- Effect of Position and Anesthetic Choice in Intraocular Pressure in Robotic GYN (Gynecologic) Oncology Patients (PHASE4)
- Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study (EARLY_PHASE1)
- Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery (NA)
- Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ketamine 1.5 CI brief — competitive landscape report
- ketamine 1.5 updates RSS · CI watch RSS
- Ajou University School of Medicine portfolio CI
Frequently asked questions about ketamine 1.5
What is ketamine 1.5?
How does ketamine 1.5 work?
What is ketamine 1.5 used for?
Who makes ketamine 1.5?
What drug class is ketamine 1.5 in?
What development phase is ketamine 1.5 in?
What are the side effects of ketamine 1.5?
What does ketamine 1.5 target?
Related
- Drug class: All NMDA receptor antagonist drugs
- Target: All drugs targeting NMDA receptor
- Manufacturer: Ajou University School of Medicine — full pipeline
- Therapeutic area: All drugs in Anesthesia, Pain Management, Psychiatry
- Indication: Drugs for General anesthesia
- Indication: Drugs for Analgesia and pain management
- Indication: Drugs for Treatment-resistant depression (sub-anesthetic doses)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing